Liver-directed treatment is associated with improved survival and increased response to immune checkpoint blockade in metastatic uveal melanoma: results from a retrospective multicenter trial
Metastases of uveal melanoma (UM) spread predominantly to the liver. Due to low response rates to systemic therapies, liver-directed therapies (LDT) are commonly used for tumor control. The impact of LDT on the response to systemic treatment is unknown. A total of 182 patients with metastatic UM tre...
Gespeichert in:
| Veröffentlicht in: | Frontiers of medicine 2023-10, Vol.17 (5), p.878-888 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 888 |
|---|---|
| container_issue | 5 |
| container_start_page | 878 |
| container_title | Frontiers of medicine |
| container_volume | 17 |
| creator | Koch, Elias A. T. Petzold, Anne Wessely, Anja Dippel, Edgar Eckstein, Markus Gesierich, Anja Gutzmer, Ralf Hassel, Jessica C. Knorr, Harald Kreuzberg, Nicole Leiter, Ulrike Loquai, Carmen Meier, Friedegund Meissner, Markus Mohr, Peter Pföhler, Claudia Rahimi, Farnaz Schadendorf, Dirk Schlaak, Max Thoms, Kai-Martin Ugurel, Selma Utikal, Jochen Weichenthal, Michael Schuler-Thurner, Beatrice Berking, Carola Heppt, Markus V. |
| description | Metastases of uveal melanoma (UM) spread predominantly to the liver. Due to low response rates to systemic therapies, liver-directed therapies (LDT) are commonly used for tumor control. The impact of LDT on the response to systemic treatment is unknown. A total of 182 patients with metastatic UM treated with immune checkpoint blockade (ICB) were included in this analysis. Patients were recruited from prospective skin cancer centers and the German national skin cancer registry (ADOReg) of the German Dermatologic Cooperative Oncology Group (DeCOG). Two cohorts were compared: patients with LDT (cohort A,
n
= 78) versus those without LDT (cohort B,
n
= 104). Data were analyzed for response to treatment, progression-free survival (PFS), and overall survival (OS). The median OS was significantly longer in cohort A than in cohort B (20.1 vs. 13.8 months;
P
= 0.0016) and a trend towards improved PFS was observed for cohort A (3.0 vs. 2.5 months;
P
= 0.054). The objective response rate to any ICB (16.7% vs. 3.8%,
P
= 0.0073) and combined ICB (14.1% vs. 4.5%,
P
= 0.017) was more favorable in cohort A. Our data suggest that the combination of LDT with ICB may be associated with a survival benefit and higher treatment response to ICB in patients with metastatic UM. |
| doi_str_mv | 10.1007/s11684-023-0993-y |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2854434893</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2854434893</sourcerecordid><originalsourceid>FETCH-LOGICAL-c415t-f15f50c8ebe115d0b05d52102c6647151244d9be18c637fcca9fe1c250c6946d3</originalsourceid><addsrcrecordid>eNp1UU1v1TAQjBCIVqU_gAuyxIVLiu3YScwNVXxUehIXOFt-zoa6jePgdYLer-OvsU-vFAkJX-zdnRmPPVX1UvArwXn3FoVoe1Vz2dTcmKY-PKnOJTeaOlI_fTyL7qy6RLzjtFQrOmOeV2dNpxrZKnFe_dqFDXI9hAy-wMBKBlcizIUFZA4x-eCO_Z-h3LIQl5w2qnDNW9jcxNw8sDB7IiG1M-CSZgRWEmHjOgPzt-DvlxRIcD8lf-8GIAKLUBwWV4Jn6wYkFGFyc4ru3VFknQqyMafIHJUlJ1zIHRllkUbBkz3IZDW46UX1bHQTwuXDflF9-_jh6_Xnevfl0831-13tldClHoUeNfc97EEIPfA914OWgkvftqoTWkilBkPD3rdNN3rvzAjCS-K0RrVDc1G9OenSD_xYAYuNAT1M5BrSilb2WqlG9aYh6Ot_oHdpzTO5s9JwQYi26wklTihPz8MMo11yiC4frOD2GLA9BWwpYHsM2B6I8-pBed1HGB4Zf-IkgDwBkEbzd8h_r_6_6m8fhLZG</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2901933678</pqid></control><display><type>article</type><title>Liver-directed treatment is associated with improved survival and increased response to immune checkpoint blockade in metastatic uveal melanoma: results from a retrospective multicenter trial</title><source>MEDLINE</source><source>Springer Online Journals Complete</source><creator>Koch, Elias A. T. ; Petzold, Anne ; Wessely, Anja ; Dippel, Edgar ; Eckstein, Markus ; Gesierich, Anja ; Gutzmer, Ralf ; Hassel, Jessica C. ; Knorr, Harald ; Kreuzberg, Nicole ; Leiter, Ulrike ; Loquai, Carmen ; Meier, Friedegund ; Meissner, Markus ; Mohr, Peter ; Pföhler, Claudia ; Rahimi, Farnaz ; Schadendorf, Dirk ; Schlaak, Max ; Thoms, Kai-Martin ; Ugurel, Selma ; Utikal, Jochen ; Weichenthal, Michael ; Schuler-Thurner, Beatrice ; Berking, Carola ; Heppt, Markus V.</creator><creatorcontrib>Koch, Elias A. T. ; Petzold, Anne ; Wessely, Anja ; Dippel, Edgar ; Eckstein, Markus ; Gesierich, Anja ; Gutzmer, Ralf ; Hassel, Jessica C. ; Knorr, Harald ; Kreuzberg, Nicole ; Leiter, Ulrike ; Loquai, Carmen ; Meier, Friedegund ; Meissner, Markus ; Mohr, Peter ; Pföhler, Claudia ; Rahimi, Farnaz ; Schadendorf, Dirk ; Schlaak, Max ; Thoms, Kai-Martin ; Ugurel, Selma ; Utikal, Jochen ; Weichenthal, Michael ; Schuler-Thurner, Beatrice ; Berking, Carola ; Heppt, Markus V.</creatorcontrib><description>Metastases of uveal melanoma (UM) spread predominantly to the liver. Due to low response rates to systemic therapies, liver-directed therapies (LDT) are commonly used for tumor control. The impact of LDT on the response to systemic treatment is unknown. A total of 182 patients with metastatic UM treated with immune checkpoint blockade (ICB) were included in this analysis. Patients were recruited from prospective skin cancer centers and the German national skin cancer registry (ADOReg) of the German Dermatologic Cooperative Oncology Group (DeCOG). Two cohorts were compared: patients with LDT (cohort A,
n
= 78) versus those without LDT (cohort B,
n
= 104). Data were analyzed for response to treatment, progression-free survival (PFS), and overall survival (OS). The median OS was significantly longer in cohort A than in cohort B (20.1 vs. 13.8 months;
P
= 0.0016) and a trend towards improved PFS was observed for cohort A (3.0 vs. 2.5 months;
P
= 0.054). The objective response rate to any ICB (16.7% vs. 3.8%,
P
= 0.0073) and combined ICB (14.1% vs. 4.5%,
P
= 0.017) was more favorable in cohort A. Our data suggest that the combination of LDT with ICB may be associated with a survival benefit and higher treatment response to ICB in patients with metastatic UM.</description><identifier>ISSN: 2095-0217</identifier><identifier>EISSN: 2095-0225</identifier><identifier>DOI: 10.1007/s11684-023-0993-y</identifier><identifier>PMID: 37432641</identifier><language>eng</language><publisher>Beijing: Higher Education Press</publisher><subject>CTLA-4 Antigen ; Humans ; Immune Checkpoint Inhibitors - therapeutic use ; Liver ; Medicine ; Medicine & Public Health ; Melanoma ; Metastasis ; Prospective Studies ; Research Article ; Skin cancer ; Skin Neoplasms</subject><ispartof>Frontiers of medicine, 2023-10, Vol.17 (5), p.878-888</ispartof><rights>The Author(s) 2023</rights><rights>2023. The Author(s).</rights><rights>The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c415t-f15f50c8ebe115d0b05d52102c6647151244d9be18c637fcca9fe1c250c6946d3</citedby><cites>FETCH-LOGICAL-c415t-f15f50c8ebe115d0b05d52102c6647151244d9be18c637fcca9fe1c250c6946d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s11684-023-0993-y$$EPDF$$P50$$Gspringer$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s11684-023-0993-y$$EHTML$$P50$$Gspringer$$Hfree_for_read</linktohtml><link.rule.ids>315,781,785,27929,27930,41493,42562,51324</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37432641$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Koch, Elias A. T.</creatorcontrib><creatorcontrib>Petzold, Anne</creatorcontrib><creatorcontrib>Wessely, Anja</creatorcontrib><creatorcontrib>Dippel, Edgar</creatorcontrib><creatorcontrib>Eckstein, Markus</creatorcontrib><creatorcontrib>Gesierich, Anja</creatorcontrib><creatorcontrib>Gutzmer, Ralf</creatorcontrib><creatorcontrib>Hassel, Jessica C.</creatorcontrib><creatorcontrib>Knorr, Harald</creatorcontrib><creatorcontrib>Kreuzberg, Nicole</creatorcontrib><creatorcontrib>Leiter, Ulrike</creatorcontrib><creatorcontrib>Loquai, Carmen</creatorcontrib><creatorcontrib>Meier, Friedegund</creatorcontrib><creatorcontrib>Meissner, Markus</creatorcontrib><creatorcontrib>Mohr, Peter</creatorcontrib><creatorcontrib>Pföhler, Claudia</creatorcontrib><creatorcontrib>Rahimi, Farnaz</creatorcontrib><creatorcontrib>Schadendorf, Dirk</creatorcontrib><creatorcontrib>Schlaak, Max</creatorcontrib><creatorcontrib>Thoms, Kai-Martin</creatorcontrib><creatorcontrib>Ugurel, Selma</creatorcontrib><creatorcontrib>Utikal, Jochen</creatorcontrib><creatorcontrib>Weichenthal, Michael</creatorcontrib><creatorcontrib>Schuler-Thurner, Beatrice</creatorcontrib><creatorcontrib>Berking, Carola</creatorcontrib><creatorcontrib>Heppt, Markus V.</creatorcontrib><title>Liver-directed treatment is associated with improved survival and increased response to immune checkpoint blockade in metastatic uveal melanoma: results from a retrospective multicenter trial</title><title>Frontiers of medicine</title><addtitle>Front. Med</addtitle><addtitle>Front Med</addtitle><description>Metastases of uveal melanoma (UM) spread predominantly to the liver. Due to low response rates to systemic therapies, liver-directed therapies (LDT) are commonly used for tumor control. The impact of LDT on the response to systemic treatment is unknown. A total of 182 patients with metastatic UM treated with immune checkpoint blockade (ICB) were included in this analysis. Patients were recruited from prospective skin cancer centers and the German national skin cancer registry (ADOReg) of the German Dermatologic Cooperative Oncology Group (DeCOG). Two cohorts were compared: patients with LDT (cohort A,
n
= 78) versus those without LDT (cohort B,
n
= 104). Data were analyzed for response to treatment, progression-free survival (PFS), and overall survival (OS). The median OS was significantly longer in cohort A than in cohort B (20.1 vs. 13.8 months;
P
= 0.0016) and a trend towards improved PFS was observed for cohort A (3.0 vs. 2.5 months;
P
= 0.054). The objective response rate to any ICB (16.7% vs. 3.8%,
P
= 0.0073) and combined ICB (14.1% vs. 4.5%,
P
= 0.017) was more favorable in cohort A. Our data suggest that the combination of LDT with ICB may be associated with a survival benefit and higher treatment response to ICB in patients with metastatic UM.</description><subject>CTLA-4 Antigen</subject><subject>Humans</subject><subject>Immune Checkpoint Inhibitors - therapeutic use</subject><subject>Liver</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Melanoma</subject><subject>Metastasis</subject><subject>Prospective Studies</subject><subject>Research Article</subject><subject>Skin cancer</subject><subject>Skin Neoplasms</subject><issn>2095-0217</issn><issn>2095-0225</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><recordid>eNp1UU1v1TAQjBCIVqU_gAuyxIVLiu3YScwNVXxUehIXOFt-zoa6jePgdYLer-OvsU-vFAkJX-zdnRmPPVX1UvArwXn3FoVoe1Vz2dTcmKY-PKnOJTeaOlI_fTyL7qy6RLzjtFQrOmOeV2dNpxrZKnFe_dqFDXI9hAy-wMBKBlcizIUFZA4x-eCO_Z-h3LIQl5w2qnDNW9jcxNw8sDB7IiG1M-CSZgRWEmHjOgPzt-DvlxRIcD8lf-8GIAKLUBwWV4Jn6wYkFGFyc4ru3VFknQqyMafIHJUlJ1zIHRllkUbBkz3IZDW46UX1bHQTwuXDflF9-_jh6_Xnevfl0831-13tldClHoUeNfc97EEIPfA914OWgkvftqoTWkilBkPD3rdNN3rvzAjCS-K0RrVDc1G9OenSD_xYAYuNAT1M5BrSilb2WqlG9aYh6Ot_oHdpzTO5s9JwQYi26wklTihPz8MMo11yiC4frOD2GLA9BWwpYHsM2B6I8-pBed1HGB4Zf-IkgDwBkEbzd8h_r_6_6m8fhLZG</recordid><startdate>20231001</startdate><enddate>20231001</enddate><creator>Koch, Elias A. T.</creator><creator>Petzold, Anne</creator><creator>Wessely, Anja</creator><creator>Dippel, Edgar</creator><creator>Eckstein, Markus</creator><creator>Gesierich, Anja</creator><creator>Gutzmer, Ralf</creator><creator>Hassel, Jessica C.</creator><creator>Knorr, Harald</creator><creator>Kreuzberg, Nicole</creator><creator>Leiter, Ulrike</creator><creator>Loquai, Carmen</creator><creator>Meier, Friedegund</creator><creator>Meissner, Markus</creator><creator>Mohr, Peter</creator><creator>Pföhler, Claudia</creator><creator>Rahimi, Farnaz</creator><creator>Schadendorf, Dirk</creator><creator>Schlaak, Max</creator><creator>Thoms, Kai-Martin</creator><creator>Ugurel, Selma</creator><creator>Utikal, Jochen</creator><creator>Weichenthal, Michael</creator><creator>Schuler-Thurner, Beatrice</creator><creator>Berking, Carola</creator><creator>Heppt, Markus V.</creator><general>Higher Education Press</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>20231001</creationdate><title>Liver-directed treatment is associated with improved survival and increased response to immune checkpoint blockade in metastatic uveal melanoma: results from a retrospective multicenter trial</title><author>Koch, Elias A. T. ; Petzold, Anne ; Wessely, Anja ; Dippel, Edgar ; Eckstein, Markus ; Gesierich, Anja ; Gutzmer, Ralf ; Hassel, Jessica C. ; Knorr, Harald ; Kreuzberg, Nicole ; Leiter, Ulrike ; Loquai, Carmen ; Meier, Friedegund ; Meissner, Markus ; Mohr, Peter ; Pföhler, Claudia ; Rahimi, Farnaz ; Schadendorf, Dirk ; Schlaak, Max ; Thoms, Kai-Martin ; Ugurel, Selma ; Utikal, Jochen ; Weichenthal, Michael ; Schuler-Thurner, Beatrice ; Berking, Carola ; Heppt, Markus V.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c415t-f15f50c8ebe115d0b05d52102c6647151244d9be18c637fcca9fe1c250c6946d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>CTLA-4 Antigen</topic><topic>Humans</topic><topic>Immune Checkpoint Inhibitors - therapeutic use</topic><topic>Liver</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Melanoma</topic><topic>Metastasis</topic><topic>Prospective Studies</topic><topic>Research Article</topic><topic>Skin cancer</topic><topic>Skin Neoplasms</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Koch, Elias A. T.</creatorcontrib><creatorcontrib>Petzold, Anne</creatorcontrib><creatorcontrib>Wessely, Anja</creatorcontrib><creatorcontrib>Dippel, Edgar</creatorcontrib><creatorcontrib>Eckstein, Markus</creatorcontrib><creatorcontrib>Gesierich, Anja</creatorcontrib><creatorcontrib>Gutzmer, Ralf</creatorcontrib><creatorcontrib>Hassel, Jessica C.</creatorcontrib><creatorcontrib>Knorr, Harald</creatorcontrib><creatorcontrib>Kreuzberg, Nicole</creatorcontrib><creatorcontrib>Leiter, Ulrike</creatorcontrib><creatorcontrib>Loquai, Carmen</creatorcontrib><creatorcontrib>Meier, Friedegund</creatorcontrib><creatorcontrib>Meissner, Markus</creatorcontrib><creatorcontrib>Mohr, Peter</creatorcontrib><creatorcontrib>Pföhler, Claudia</creatorcontrib><creatorcontrib>Rahimi, Farnaz</creatorcontrib><creatorcontrib>Schadendorf, Dirk</creatorcontrib><creatorcontrib>Schlaak, Max</creatorcontrib><creatorcontrib>Thoms, Kai-Martin</creatorcontrib><creatorcontrib>Ugurel, Selma</creatorcontrib><creatorcontrib>Utikal, Jochen</creatorcontrib><creatorcontrib>Weichenthal, Michael</creatorcontrib><creatorcontrib>Schuler-Thurner, Beatrice</creatorcontrib><creatorcontrib>Berking, Carola</creatorcontrib><creatorcontrib>Heppt, Markus V.</creatorcontrib><collection>Springer Nature OA/Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Frontiers of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Koch, Elias A. T.</au><au>Petzold, Anne</au><au>Wessely, Anja</au><au>Dippel, Edgar</au><au>Eckstein, Markus</au><au>Gesierich, Anja</au><au>Gutzmer, Ralf</au><au>Hassel, Jessica C.</au><au>Knorr, Harald</au><au>Kreuzberg, Nicole</au><au>Leiter, Ulrike</au><au>Loquai, Carmen</au><au>Meier, Friedegund</au><au>Meissner, Markus</au><au>Mohr, Peter</au><au>Pföhler, Claudia</au><au>Rahimi, Farnaz</au><au>Schadendorf, Dirk</au><au>Schlaak, Max</au><au>Thoms, Kai-Martin</au><au>Ugurel, Selma</au><au>Utikal, Jochen</au><au>Weichenthal, Michael</au><au>Schuler-Thurner, Beatrice</au><au>Berking, Carola</au><au>Heppt, Markus V.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Liver-directed treatment is associated with improved survival and increased response to immune checkpoint blockade in metastatic uveal melanoma: results from a retrospective multicenter trial</atitle><jtitle>Frontiers of medicine</jtitle><stitle>Front. Med</stitle><addtitle>Front Med</addtitle><date>2023-10-01</date><risdate>2023</risdate><volume>17</volume><issue>5</issue><spage>878</spage><epage>888</epage><pages>878-888</pages><issn>2095-0217</issn><eissn>2095-0225</eissn><abstract>Metastases of uveal melanoma (UM) spread predominantly to the liver. Due to low response rates to systemic therapies, liver-directed therapies (LDT) are commonly used for tumor control. The impact of LDT on the response to systemic treatment is unknown. A total of 182 patients with metastatic UM treated with immune checkpoint blockade (ICB) were included in this analysis. Patients were recruited from prospective skin cancer centers and the German national skin cancer registry (ADOReg) of the German Dermatologic Cooperative Oncology Group (DeCOG). Two cohorts were compared: patients with LDT (cohort A,
n
= 78) versus those without LDT (cohort B,
n
= 104). Data were analyzed for response to treatment, progression-free survival (PFS), and overall survival (OS). The median OS was significantly longer in cohort A than in cohort B (20.1 vs. 13.8 months;
P
= 0.0016) and a trend towards improved PFS was observed for cohort A (3.0 vs. 2.5 months;
P
= 0.054). The objective response rate to any ICB (16.7% vs. 3.8%,
P
= 0.0073) and combined ICB (14.1% vs. 4.5%,
P
= 0.017) was more favorable in cohort A. Our data suggest that the combination of LDT with ICB may be associated with a survival benefit and higher treatment response to ICB in patients with metastatic UM.</abstract><cop>Beijing</cop><pub>Higher Education Press</pub><pmid>37432641</pmid><doi>10.1007/s11684-023-0993-y</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2095-0217 |
| ispartof | Frontiers of medicine, 2023-10, Vol.17 (5), p.878-888 |
| issn | 2095-0217 2095-0225 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2854434893 |
| source | MEDLINE; Springer Online Journals Complete |
| subjects | CTLA-4 Antigen Humans Immune Checkpoint Inhibitors - therapeutic use Liver Medicine Medicine & Public Health Melanoma Metastasis Prospective Studies Research Article Skin cancer Skin Neoplasms |
| title | Liver-directed treatment is associated with improved survival and increased response to immune checkpoint blockade in metastatic uveal melanoma: results from a retrospective multicenter trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-15T15%3A41%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Liver-directed%20treatment%20is%20associated%20with%20improved%20survival%20and%20increased%20response%20to%20immune%20checkpoint%20blockade%20in%20metastatic%20uveal%20melanoma:%20results%20from%20a%20retrospective%20multicenter%20trial&rft.jtitle=Frontiers%20of%20medicine&rft.au=Koch,%20Elias%20A.%20T.&rft.date=2023-10-01&rft.volume=17&rft.issue=5&rft.spage=878&rft.epage=888&rft.pages=878-888&rft.issn=2095-0217&rft.eissn=2095-0225&rft_id=info:doi/10.1007/s11684-023-0993-y&rft_dat=%3Cproquest_cross%3E2854434893%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2901933678&rft_id=info:pmid/37432641&rfr_iscdi=true |